“Both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint. Sage plans to submit an NDA in 1H18. Brexanolone has both Breakthrough status and PRIME designation and we expect FDA approval/launch in 2H18. We have modest expectations for overall commercial opportunity w/ brexanolone as a 60-hr IV infusion, but we highlight that it will address an unmet need as the first drug approved for PPD. We ultimately expect oral ‘217 to replace brexanolone for this indication and view outcome as a positive for ‘217 program as mechanism is now validated. We still see significant upside opportunity for Sage shares w/ Phase 2 ‘217 MDD data reporting out by YE. Positive results would signify potential for broad utility across mood disorders.”,” the firm’s analyst commented.
ATRA has been the subject of a number of other research reports. Goldman Sachs Group reiterated a neutral rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Jefferies Group reiterated a buy rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Zacks Investment Research lowered Atara Biotherapeutics from a buy rating to a hold rating in a research note on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a strong sell rating to a sell rating in a research note on Friday, September 1st. Finally, BidaskClub lowered Atara Biotherapeutics from a hold rating to a sell rating in a research note on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of $24.40.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). analysts predict that Atara Biotherapeutics will post -4 EPS for the current year.
In other news, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $13.47, for a total value of $59,268.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at approximately $9,937,721.49. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $15.30, for a total value of $91,800.00. Following the completion of the transaction, the executive vice president now owns 349,305 shares of the company’s stock, valued at approximately $5,344,366.50. The disclosure for this sale can be found here. Insiders have sold a total of 45,988 shares of company stock worth $674,308 over the last 90 days. 16.20% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Eagle Asset Management Inc. increased its stake in Atara Biotherapeutics by 17.8% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after buying an additional 225,367 shares in the last quarter. Neuberger Berman Group LLC increased its stake in Atara Biotherapeutics by 15.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after buying an additional 147,061 shares in the last quarter. Vanguard Group Inc. increased its stake in Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after buying an additional 13,952 shares in the last quarter. Artal Group S.A. increased its stake in Atara Biotherapeutics by 20.0% during the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after buying an additional 100,000 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Atara Biotherapeutics by 12.0% during the 2nd quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock worth $4,183,000 after buying an additional 32,065 shares in the last quarter. Institutional investors own 85.61% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with our FREE daily email newsletter.